melanotan dangerous HPRA Warns of 2 in Tanning Products Reminder of serious health risks
Description
[CrossRef] 56
Study Design In this multicenter, double-blind, placebo-controlled trial, patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive a fixed-dose combination tablet containing 400 mg of sofosbuvir and 100 mg of velpatasvir, administered orally once daily for 12 weeks, or a placebo tablet to match the active treatment once daily for 12 weeks
Privacy and security built in
Eur Heart J (2023) 44(39):417482
